top of page
Home: Welcome
My view on what's going on in the financial markets and the global economy, and a few other things that might interest me from time to time.

Search

tim@emorningcoffee.com
Jan 293 min read
DeepSeek, ASML earnings, Mag 7 earnings and FOMC decision
DeepSeek wrecks outlook for AI companies; Mag 7 companies MSFT, META, TSLA and AAPL report earnings; FOMC expected to hold rates
14
0

tim@emorningcoffee.com
Jan 227 min read
Portfolio update: 4Q2024 and full year
This article contains an update of my 2024 portfolio performance. My returns were decent but not as good as they should have been.
23
0

tim@emorningcoffee.com
Jan 31 min read
Summary of 2024 in tables
This article contains a summary of full-year 2024 performance of the indices and assets tracked by EMC, plus historical data, too.
52
0

tim@emorningcoffee.com
Dec 31, 20248 min read
2024 market and asset performance vs my expectations: how'd I do?
I "guessed" at how markets would perform in 2024 last year at this time. Some I got right, some I got wrong, not different from the pros.
57
0

tim@emorningcoffee.com
Oct 9, 20249 min read
Portfolio update: 3Q2024
This is the update of my personal portfolio for the most recent quarter ended September 30, 2024.Â
93
0

tim@emorningcoffee.com
Jul 24, 20248 min read
Portfolio update: 1H2024
This is an update of my personal portfolio performance in 2Q2024 and 1H2024, good on the surface but worse than the indices would suggest.
75
0

tim@emorningcoffee.com
May 2, 202414 min read
Is fine wine a good investment?
The 2024 en primeur campaign for Bordeaux is just starting. But is fine wine really a good investment? I don't think so anymore.
542
4

tim@emorningcoffee.com
Apr 10, 20248 min read
Portfolio update: 1Q2024
This is an update about my personal portfolio during and at the end of 1Q2024. It also discusses performance which I consider disappointing.
74
0

tim@emorningcoffee.com
Mar 18, 20248 min read
Anti-obesity medications: part 3, valuations of LLY and NVO
This is the 3rd and final article focused on anti-obesity drugs. It looks at valuations of shares of the two giants in this biz, LLY & NVO.
59
0
Home: Blog2
bottom of page